"Immune Epitope Database and Analysis Resource Program: Proving Intuitive Access To Comprehensive Epitope Data And Tools"

Dr. Alessandro Sette
La Jolla Institute for Immunology and Allergy
La Jolla, CA, USA

Dr. Sette started at LIAI in 2002 as the Head of the Initiative for Emerging Diseases and Biodefense. In 2003 he became the Head of the Division of Translational Immunology. At LIAI, Dr. Sette’s research focuses on the identification of epitopes, working to understand how vaccines should be constructed. The team’s work is focused on the study of allergies, emerging disease threats, such as SARS, arena viruses, smallpox and flu viruses, diseases of worldwide significance such as tuberculosis, dengue and malaria. A major focus of the Sette’s group is also the design and population of the Immune Epitope Database, developed under a NIAID contract. The database allows researchers around the world to quickly access key information on the way the body responds to disease-causing agents, including those that are responsible for emerging infectious diseases, allergic reactions, autoimmune diseases and transplant rejections. By allowing researchers to share and analyze data in this unprecedented manner, the database provides an important tool for accelerating the development and improvement of vaccines.

Dr. Sette received his degree in Biological Sciences from the University of Roma, Laboratory of Pathology in 1984. In 1984, Dr. Sette was a Postdoctoral Fellow in the same laboratory. From 1986-1988, he joined The National Jewish Center for Immunology and Respiratory Medicine in Denver, in the USA as a post-doctoral fellow. In the 1988-2002 period he was Director of Immunology of Cyte corporation and founder and Chief Scientific Officer of Epimmune Corp. Dr. Sette is a member of numerous grant review panels and editorial advisory boards, and a reviewer for many scientific publications. He was awarded the 51st Oregon State University Biological Colloquium Award, the American Association of Immunologists Investigator Award, the American Liver Foundation Award for Biotechnology Companies, and the International Immunomics and Immunogenics Society Award. He is coinventor of over 20 US issued patents and coauthored over 400 peer review articles.